Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States

PharmacoEconomics - United Kingdom
doi 10.1007/s40273-019-00812-6
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

Advances in Therapy
MedicinePharmacology
2019English

Pcn142 - Cost-Effectiveness Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn71 - Budget Impact Analysis of Inotuzumab Ozogamicin for the Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Bulgaria

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Initial Experience With CMC-544 (Inotuzumab Ozogamicin) in Pediatric Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2013English

Pcn170 - Cost-Effectiveness of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Canadian Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Pcn77 - Budget Impact Analysis of Blinatumomab for the Treatment of Pediatric Patients With Philadelphia Negative Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in Mexico

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Efficacy and Safety Analysis by Age Cohort of Inotuzumab Ozogamicin in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Enrolled in INO-VATE

Cancer
Cancer ResearchOncology
2018English

Pcn146 - Inotuzumab Ozogamicin in Patients With Relapsed or Refractory (R/R) Acute Lymphocytic Leukemia (All): Establishing a Value-Based Cost – Preliminary Results

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

FDA Approval: Blinatumomab for Patients With B-Cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission With Minimal Residual Disease

Clinical Cancer Research
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy